Literature DB >> 18177845

Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology.

Alison Fenney1, Mandar S Jog, Christian Duval.   

Abstract

Our goal was to determine whether bradykinesia is present in choreic adult-onset Huntington's disease (HD) patients, and determine the impact of chorea on their voluntary movements. We recorded whole-body involuntary movements (WBIM) and voluntary motor acts simultaneously, using a magnetic tracker system, in 15 choreic HD patients and 15 healthy age- and gender-matched control subjects. Participants were asked to perform two distinct tasks; a manual-tracking (MT) task yielding a measure of chorea intrusion during accurate movements, and a rapid alternating movement (RAM) task, yielding measures of bradykinesia. Results show that patients with HD presented with deviations from the target that hindered their ability to match the target velocity during the MT task. Furthermore, error in performance was correlated with the amplitude of whole-body chorea (Rho=0.67), illustrating the deleterious effect of chorea during accurate movements. However, patients with choreic HD presented with significantly higher RAM range and velocity than matched controls, therefore ruling out the idea that bradykinesia is a systematic feature of HD even when chorea is predominant. The present results imply that patients may have benefited from an intact direct pathway ("select ON" pathway in the focused attention model of basal ganglia function) that allowed them to supersede any dysfunctions associated with the progressive alteration of the "control function" (striatal-globus pallidus-subthalamic) pathway responsible for generating the chorea. Finally, the present results suggest that patients with adult-onset HD having chorea would greatly benefit from improved treatments aiming at reducing their involuntary movements while maintaining proper motor function.

Entities:  

Mesh:

Year:  2007        PMID: 18177845     DOI: 10.1016/j.brainres.2007.12.005

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia.

Authors:  Rena K Mann; Roderick Edwards; Julie Zhou; Alison Fenney; Mandar Jog; Christian Duval
Journal:  Exp Brain Res       Date:  2012-03-21       Impact factor: 1.972

2.  An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease.

Authors:  Jean-Marc Burgunder; Mark Guttman; Susan Perlman; Nathan Goodman; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-08-30

3.  Effect of tetrabenazine on motor function in patients with huntington disease.

Authors:  Joseph M Ferrara; Giovanni Mostile; Christine Hunter; Octavian R Adam; Joseph Jankovic
Journal:  Neurol Ther       Date:  2012-09-29

4.  A Grey Box Neural Network Model of Basal Ganglia for Gait Signal of Patients with Huntington Disease.

Authors:  Abbas Pourhedayat; Yashar Sarbaz
Journal:  Basic Clin Neurosci       Date:  2016-04

5.  Do Bradykinesia and Tremor Interfere in Voluntary Movement of Essential Tremor Patients? Preliminary Findings.

Authors:  Etienne Goubault; Hung P Nguyen; Fouaz S Ayachi; Sarah Bogard; Christian Duval
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-06-22

6.  Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.

Authors:  Etienne Goubault; Hung P Nguyen; Sarah Bogard; Pierre J Blanchet; Erwan Bézard; Claude Vincent; Mélanie Langlois; Christian Duval
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 7.  Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Authors:  Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval
Journal:  BMC Med       Date:  2013-03-20       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.